The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy

2010 ◽  
Vol 19 (4) ◽  
pp. 415-422 ◽  
Author(s):  
Christina M. Schilder ◽  
Caroline Seynaeve ◽  
Sabine C. Linn ◽  
Willem Boogerd ◽  
Chad M. Gundy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Postmenopausal Breast Cancer ◽  
Adjuvant Systemic Therapy ◽  
Breast Cancer Patients ◽  
Reference Groups ◽  
The Impact

scholarly journals Cognitive impairment after cytotoxic chemotherapy

2019 ◽  
Vol 7 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Petra Huehnchen ◽  
Antonia van Kampen ◽  
Wolfgang Boehmerle ◽  
Matthias Endres
Keyword(s):  
Breast Cancer ◽  
Colon Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Cytotoxic Chemotherapy ◽  
Cytotoxic Drugs ◽  
Cytotoxic Agents ◽  
Cancer Type ◽  
Breast Cancer Patients ◽  
The Impact

Abstract Background Neurotoxicity is a frequent side effect of cytotoxic chemotherapy and affects a large number of patients. Despite the high medical need, few research efforts have addressed the impact of cytotoxic agents on cognition (ie, postchemotherapy cognitive impairment; PCCI). One unsolved question is whether individual cytotoxic drugs have differential effects on cognition. We thus examine the current state of research regarding PCCI. Neurological symptoms after targeted therapies and immunotherapies are not part of this review. Methods A literature search was conducted in the PubMed database, and 1215 articles were reviewed for predefined inclusion and exclusion criteria. Thirty articles were included in the systematic review. Results Twenty-five of the included studies report significant cognitive impairment. Of these, 21 studies investigated patients with breast cancer. Patients mainly received combinations of 5-fluorouracil, epirubicin, cyclophosphamide, doxorubicin, and taxanes (FEC/FEC-T). Five studies found no significant cognitive impairment in chemotherapy patients. Of these, 2 studies investigated patients with colon cancer receiving 5-fluorouracil and oxaliplatin (FOLFOX). Independent risk factors for PCCI were patient age, mood alterations, cognitive reserve, and the presence of apolipoprotein E e4 alleles. Conclusions There is evidence that certain chemotherapy regimens cause PCCI more frequently than others as evidenced by 21 out of 23 studies in breast cancer patients (mainly FEC-T), whereas 2 out of 3 studies with colon cancer patients (FOLFOX) did not observe significant changes. Further studies are needed defining patient cohorts by treatment protocol in addition to cancer type to elucidate the effects of individual cytotoxic drugs on cognitive functions.

scholarly journals Novel Prognostic Implications of PAQR3 Expression in Breast Cancer after Curative Resection and Systemic Therapy

2021 ◽  
Author(s):  
Shiyan Zeng ◽  
Sun Lei ◽  
Yun Xiao ◽  
Qian Wang ◽  
Purong Zhang
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Curative Resection ◽  
Tumor Grade ◽  
Breast Cancer Patients ◽  
Internal Validation ◽  
Online Databases ◽  
Predictive Role ◽  
The Impact

Abstract Background: This study aimed to explore the impact of progestin and adipoQ receptor 3 (PAQR3) on the outcomes for breast cancer patients who received curative resection and systemic therapy.Methods: The online databases consisting of 2,352 breast cancer patients were used to explore the association between PAQR3 expression and clinicopathological features. Univariate and multivariate survival analysis were performed to identify the survival predictive role of PAQR3. The internal validation strategies were applied.Results: PAQR3 expression was inversely correlated with estrogen receptor (ER) expression (P<0.0001), progesterone receptor (PR) expression (P<0.0001) and tumor grade (P<0.0001). Higher PAQR3 expression independently predicted shorter overall survival (OS) (hazard ratio (HR)=1.20, 95% confidence interval (CI)=1.06-1.37, P=0.0055) and recurrence free survival (RFS) (HR=1.28, 95%CI=1.04-1.45, P=0.0170) in breast cancer patients. In ER+ breast cancer and PR+ breast cancer, PAQR3 was associated with shorter OS (ER+: HR=1.28, 95%CI=1.11-1.48, P=0.0006; PR+: HR=1.30, 95%CI=1.09-1.56, P=0.0037) and RFS (ER+: HR=1.46, 95%CI=1.19-1.77, P=0.0002; PR+: HR=1.48, 95%CI=1.16-1.89, P=0.0016), but no such prognostic values of PAQR3 expression were found in ER- breast cancer and PR- breast cancer.Conclusions: PAQR3 serves as an independent outcomes predictor for breast cancer.

Sign in / Sign up

Export Citation Format

Share Document